Bujalska Magdalena
Department of Pharmacodynamics, Medical University of Warsaw, Warsaw, Poland.
Pharmacology. 2008;82(3):193-200. doi: 10.1159/000156485. Epub 2008 Sep 23.
The effect of CB-1 and CB-2 receptor agonists, as well as an influence of a non-selective inhibitor of nitric oxide synthase (NOS), L-NOArg, and an inhibitor acting preferentially on cyclooxygenase-1 (COX-1), indomethacin, on the action of cannabinoid receptor agonists in a streptozotocin (STZ)-induced neuropathic model was investigated. When administered alone, a non-selective cannabinoid receptor agonist, WIN 55,212-2, a potentially selective CB-1 cannabinoid receptor agonist, Met-F-AEA, and a selective CB-2 cannabinoid receptor agonist, AM1241, dose-dependently reduced STZ-induced hyperalgesia. The results of the present study also demonstrated that inhibitors of COX and NOS increase antihyperalgesic activity of low doses of CB-1 and CB-2 receptor agonists. Hypothetical consequences of this phenomenon are discussed.
研究了CB-1和CB-2受体激动剂的作用，以及一氧化氮合酶（NOS）的非选择性抑制剂L-精氨酸甲酯（L-NOArg）和优先作用于环氧化酶-1（COX-1）的抑制剂吲哚美辛对链脲佐菌素（STZ）诱导的神经病变模型中大麻素受体激动剂作用的影响。单独给药时，非选择性大麻素受体激动剂WIN 55,212-2、潜在的选择性CB-1大麻素受体激动剂Met-F-AEA和选择性CB-2大麻素受体激动剂AM1241均剂量依赖性地减轻STZ诱导的痛觉过敏。本研究结果还表明，COX和NOS抑制剂可增强低剂量CB-1和CB-2受体激动剂的抗痛觉过敏活性。文中讨论了这一现象的假设性后果。
